Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Chrisf720 Sep. 10 at 11:00 AM

$CABA we gonna be able to hear this conference?

1 · Reply

oi0o Sep. 10 at 6:04 AM

$CABA coming good news?

0 · Reply

Kawasaki1 Sep. 10 at 1:42 AM

$CABA Sure it's speculative but my GOD, the upside is HUGE! LOTS o' possibilities = Partner, take-over target, buyout or just fly on it's own! $NDAQ

0 · Reply

LifeisaMeme Sep. 10 at 12:44 AM

$CABA Guys I sold my caba and I'm going all in on Monday for the Los Angeles Chargers to beat the Las Vegas Raiders. Am I locked in ? Do you guys think I will get slapped up ? Comment below LMAOOOOOOO. If I win I'm going to do a few more bets, then buy CABA again.

0 · Reply

maooooo Sep. 9 at 4:27 PM

$CABA little slow today because the conferences are mañana!

0 · Reply

LifeisaMeme Sep. 9 at 2:18 PM

$CABA Just announce a crypto treasury for fuck sake.

0 · Reply

WastedTrader Sep. 9 at 3:52 AM

$CABA we're ripping this week

0 · Reply

Moonman321 Sep. 9 at 3:49 AM

$CABA 💪🏻 it has to run this week CPI Thursday 8:30 AM I think we’re going run into it I’m filling it for tomorrow

0 · Reply

LifeisaMeme Sep. 8 at 10:52 PM

$CABA Please $5 by December omfg

0 · Reply

Chrisf720 Sep. 8 at 7:10 PM

$CABA Im thinking $2+ by end of week

0 · Reply

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 4 weeks ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 5 weeks ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 3 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 3 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 3 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 3 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 3 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 4 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 6 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 6 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 7 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 7 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 7 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 7 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 8 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 11 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 4:35 PM EDT - 2 years ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Chrisf720 Sep. 10 at 11:00 AM

$CABA we gonna be able to hear this conference?

1 · Reply

oi0o Sep. 10 at 6:04 AM

$CABA coming good news?

0 · Reply

Kawasaki1 Sep. 10 at 1:42 AM

$CABA Sure it's speculative but my GOD, the upside is HUGE! LOTS o' possibilities = Partner, take-over target, buyout or just fly on it's own! $NDAQ

0 · Reply

LifeisaMeme Sep. 10 at 12:44 AM

0 · Reply

maooooo Sep. 9 at 4:27 PM

$CABA little slow today because the conferences are mañana!

0 · Reply

LifeisaMeme Sep. 9 at 2:18 PM

$CABA Just announce a crypto treasury for fuck sake.

0 · Reply

WastedTrader Sep. 9 at 3:52 AM

$CABA we're ripping this week

0 · Reply

Moonman321 Sep. 9 at 3:49 AM

$CABA 💪🏻 it has to run this week CPI Thursday 8:30 AM I think we’re going run into it I’m filling it for tomorrow

0 · Reply

LifeisaMeme Sep. 8 at 10:52 PM

$CABA Please $5 by December omfg

0 · Reply

Chrisf720 Sep. 8 at 7:10 PM

$CABA Im thinking $2+ by end of week

0 · Reply

Moonman321 Sep. 8 at 7:02 PM

$CABA this thread is about to get busy busy While everybody’s waiting for confirmation I’m in the green holding over 70,000 shares If we hit $20 a share Million dollar stock for me What an opportunity of a lifetime We all know how quick this thing moves It went from its low to 25 within two months a year ago or less I think we’ll hit 25 quicker than last time Let’s get that rate cut Little over 10% short, those rats will be trapped Very soon

0 · Reply

Moonman321 Sep. 8 at 6:46 PM

$CABA $NVDA CPI Thursday my bad Let’s get that power hour coming up $QBTS $CABA 💥

0 · Reply

Ahouli09 Sep. 8 at 6:32 PM

$CABA

1 · Reply

Ahouli09 Sep. 8 at 11:52 AM

$CABA

0 · Reply

Winning_calls Sep. 8 at 3:21 AM

$CABA pick me up @ $1.75

1 · Reply

Moonman321 Sep. 8 at 1:16 AM

$SHOP $CABA $QBTS what a great company and stock Bought a nice position for $42 January 2023 and never sold a share Up over 300% 💥 Small caps are ready to takeoff and Shop will benefit from it tremendously Don’t fight the fed ✂️ $CABA $QBTS

0 · Reply

Moonman321 Sep. 7 at 10:37 PM

$CABA $CABA $NVDA The 🐑 🐻 are going to get an ass whooping this week Pharma chump lol CPI Wednesday morning, 830 If we get a good CPI which we have been, but if we surprise to the downside, the market will crush it If it’s a little hot, we’re still off to the races The Fed has two mandates Full employment Stable prices The employment numbers were soft for the last couple months Guaranteed rate cut this month And I’m going to say 50 basis points And then slow Powell will cut again 25 basis points this year Early next year Trump will have a rate cutting machine to take the place of Jerome Powell 💪🏻 We’re going into a 10 year. 🐂 🏃‍♀️ Opportunity of a lifetime I’m lucky enough to have 2/Covid/financial crisis 💰 💰 Small cap heaven Rotation time 💥

0 · Reply

LifeisaMeme Sep. 7 at 4:19 AM

$CABA OMG Steve is working overtime LMAO. Lock in Steve I need one good trade to end the year. I'm locked the fuck in. You can always count on Steve omg LMAOOOOOOOOOOOo

0 · Reply

FiercePamela Sep. 6 at 6:27 PM

SKYQ is ready to go big soon, super undervalued, This has squeeze written all over it! Upcoming catalyst ahead! Sky Quarry Announces Strategic Digital Asset Initiative “Company Plans to Explore Cryptocurrency Treasury Model, bringing blockchain technologies into critical sectors like energy.” Huge! SKYQ is trading under book value and the chart is curling. No dilution risk makes this even better. $CYN $GRI $RUN $CABA Watching, but main ticker thats rdy to go is SKYQ.

0 · Reply

WoldanStanford Sep. 6 at 5:15 PM

$CABA

0 · Reply

Mulhollandr Sep. 6 at 3:22 AM

$CABA friends. I’ve been in and out of caba since 2019. It has given me my greatest return of any stock I’ve ever invested in. Learned some hard lessons elsewhere since then (F U BLUE). I’m looking forward to riding caba back to all time highs in the near future. However, in the mean time I would encourage you to look at CLNN. Upcoming catalysts and current trend is looking wildly attractive. Good luck all!

0 · Reply

maooooo Sep. 5 at 10:34 PM

Here is yesterday’s power point. $CABA https://www.sec.gov/Archives/edgar/data/1759138/000175913825000007/caba-ex99_1.htm

0 · Reply

Market Cap	153.66M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	716,700
Avg Vol	1,354,062
Day's Range	N/A - N/A
Shares Out	91.47M
Stochastic %K	71%
Beta	2.86
Analysts	Strong Sell
Price Target	$11.55